^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    labetuzumab govitecan (IMMU-130)

    i
    Other names: IMMU-130, anti-CEACAM5-SN-38, hMN-14-SN38, labetuzumab-SN38 conjugate, SN38-labetuzumab conjugate, hMN-14-SN38 antibody-drug conjugate
    Company:
    Gilead
    Drug class:
    Topoisomerase I inhibitor, CEACAM5-targeted antibody-drug conjugate
    Related drugs:
    6ms
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer. (PubMed, J Nucl Med)
    [89Zr]Zr-DFO-labetuzumab imaging was able to clearly delineate both neuroendocrine H660 xenografts and AR- DU145 in vivo but could not detect the AR-positive xenograft LNCaP. Immuno-PET imaging with [89Zr]Zr-DFO-labetuzumab is a promising diagnostic tool for AR- prostate cancer.
    Journal
    |
    AR (Androgen receptor) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    labetuzumab govitecan (IMMU-130)
    10ms
    Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=92, Terminated, Gilead Sciences | Withdrawn --> Terminated
    Trial termination • Metastases
    |
    Trodelvy (sacituzumab govitecan-hziy) • labetuzumab govitecan (IMMU-130)